Nausea: Labs, Diagnosis, and Next Steps

Why Nausea Happens: The Neurophysiology

Nausea originates from a coordinated signal relay between the chemoreceptor trigger zone (CTZ) in the area postrema, the nucleus tractus solitarius, and the vomiting center in the medulla oblongata. These brainstem structures receive input from four distinct pathways: vagal and splanchnic afferents from the GI tract, vestibular system signals, higher cortical centers (anxiety, anticipation, pain), and circulating toxins or drugs that cross the blood-brain barrier at the area postrema [1].

The CTZ sits outside the blood-brain barrier. This anatomical detail matters because it means circulating substances (uremic toxins, opioids, chemotherapy agents, ketones) can directly activate it without needing to cross into the central nervous system [1]. Serotonin (5-HT3), dopamine (D2), substance P (NK1), and histamine (H1) receptors all participate in nausea signaling, which explains why different antiemetic drug classes target different receptor types [2].

Understanding which pathway is driving nausea helps direct the workup. Visceral afferent-driven nausea (from gastric distension, bowel obstruction, or hepatobiliary disease) typically worsens with eating and associates with abdominal pain. Vestibular nausea worsens with head movement. CTZ-mediated nausea from metabolic causes tends to be constant, positional independence being a distinguishing feature [2].

Common Causes of Nausea by Organ System

The differential diagnosis for nausea spans virtually every organ system. A 2021 systematic review in Alimentary Pharmacology & Therapeutics found that among patients presenting to gastroenterology clinics with chronic unexplained nausea (defined as nausea on at least 3 days per week for 12 or more weeks), functional dyspepsia accounted for 34%, gastroparesis for 19%, and medication side effects for 15% [3].

Gastrointestinal causes include GERD, peptic ulcer disease, gastroparesis, small bowel obstruction, acute pancreatitis, cholecystitis, and hepatitis. GERD alone affects an estimated 20% of the U.S. adult population, and nausea is a presenting symptom in roughly 30% of those cases according to an analysis published in Gastroenterology [4].

Metabolic and endocrine causes are frequently overlooked. Diabetic ketoacidosis, uremia (BUN typically exceeding 60 mg/dL), hypercalcemia, hyponatremia, adrenal insufficiency, and thyroid disorders all produce nausea through CTZ activation or autonomic dysfunction [5]. Pregnancy remains the most common endocrine cause in women of reproductive age, with nausea affecting 50-80% of pregnancies, most commonly between weeks 6 and 12 [6].

Medication-induced nausea deserves specific attention. GLP-1 receptor agonists like semaglutide cause nausea in 40-70% of patients during dose titration, per the STEP-1 trial (N=1,961), though this typically attenuates within 4-8 weeks [7]. Metformin, SSRIs, opioids, antibiotics (particularly erythromycin and metronidazole), and iron supplements are other frequent offenders. A thorough medication reconciliation should precede any lab workup.

Neurological causes include migraine (nausea is a diagnostic criterion in ICHD-3), raised intracranial pressure, and vestibular disorders such as benign paroxysmal positional vertigo and Meniere disease [8].

Which Labs to Order for Persistent Nausea

The American Gastroenterological Association (AGA) recommends a stepwise laboratory evaluation when nausea persists beyond 48-72 hours without an obvious cause or when nausea recurs frequently over weeks [9]. The initial panel should include:

Basic metabolic panel (BMP). This captures sodium, potassium, bicarbonate, BUN, creatinine, and glucose. Hyponatremia (Na <130 mEq/L) and uremia are both direct CTZ stimulants. Elevated glucose may point toward diabetic gastroparesis or ketoacidosis [5].

Complete blood count (CBC). Leukocytosis suggests infection or inflammation. Anemia may indicate chronic GI blood loss, pointing toward ulcer disease or malignancy. A platelet count above 400,000/μL can signal an underlying inflammatory or myeloproliferative process [9].

Hepatic function panel. AST, ALT, alkaline phosphatase, total bilirubin, and albumin. ALT exceeding three times the upper limit of normal raises concern for acute hepatitis. An isolated alkaline phosphatase elevation with normal transaminases suggests biliary obstruction [10].

Lipase. More specific than amylase for acute pancreatitis. A lipase level three or more times the upper limit of normal has a sensitivity of 82-100% for acute pancreatitis, according to a meta-analysis in Pancreas [11].

Thyroid-stimulating hormone (TSH). Both hyperthyroidism and hypothyroidism cause nausea, though the mechanisms differ. Hyperthyroidism accelerates gastric motility while hypothyroidism slows it [12].

Urinalysis. Screens for urinary tract infection, ketonuria, and proteinuria. Ketonuria with hyperglycemia warrants immediate evaluation for DKA.

Beta-hCG. Mandatory in all women of reproductive age, regardless of reported contraceptive use. The American College of Obstetricians and Gynecologists (ACOG) reinforces this as standard of care in their 2018 Practice Bulletin on nausea and vomiting of pregnancy [6].

Dr. Brian Lacy, a gastroenterologist at the Mayo Clinic and co-author of the ACG clinical guideline on gastroparesis, has stated: "A pregnancy test and basic metabolic panel should be reflexive in any nausea workup. Missing hyponatremia or an ectopic pregnancy because the clinician jumped straight to endoscopy is an avoidable error" [13].

Second-Tier Labs and When to Add Them

If the initial panel returns normal and nausea persists beyond 2-4 weeks, the workup expands. The AGA's 2023 clinical practice update on chronic nausea and vomiting recommends considering [9]:

Cortisol (morning serum) or ACTH stimulation test. Adrenal insufficiency affects an estimated 5 per 10,000 adults in Western countries and presents with nausea, fatigue, and orthostatic hypotension. A morning cortisol below 3 μg/dL is highly suggestive; values between 3 and 15 μg/dL require cosyntropin stimulation testing [14].

Celiac serologies (tissue transglutaminase IgA with total IgA). Celiac disease prevalence in the U.S. is approximately 0.7-1%, and nausea is present in up to 44% of newly diagnosed adults, per a 2019 study in the American Journal of Gastroenterology [15]. IgA deficiency (present in 2-3% of celiac patients) produces false-negative tTG-IgA results, which is why total IgA should always accompany the test.

Hemoglobin A1c. Even without overt hyperglycemia on BMP, an A1c of 6.5% or higher confirms diabetes, a condition strongly associated with gastroparesis and autonomic neuropathy affecting the GI tract [16].

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Elevated inflammatory markers in the setting of nausea and abdominal pain raise suspicion for inflammatory bowel disease, particularly Crohn disease affecting the proximal small bowel or stomach [17].

Helicobacter pylori testing. Stool antigen or urea breath test. H. pylori infects roughly 35% of the U.S. population and causes chronic gastritis, which can present as isolated nausea without pain. The ACG recommends testing and treating in any patient with uninvestigated dyspepsia or nausea [18].

Imaging and Specialized Diagnostic Testing

When laboratory results fail to explain persistent nausea, or when alarm features are present, imaging becomes the next step.

Upper endoscopy (EGD) is indicated when nausea lasts longer than 4 weeks with any alarm feature (unintentional weight loss, dysphagia, hematemesis, iron-deficiency anemia, new onset after age 55) [18]. The ACG's 2017 guideline on dyspepsia recommends EGD as first-line investigation in patients 60 years or older with new-onset symptoms, a threshold recently updated from the previous age cutoff of 55 in some guideline versions [18].

Gastric emptying scintigraphy (GES) is the gold standard for diagnosing gastroparesis. The test involves ingesting a radiolabeled solid meal (typically egg substitute with toast and jam) and measuring gastric retention at 1, 2, and 4 hours. Retention of more than 10% of the meal at 4 hours confirms delayed gastric emptying, per the joint ANMS/SNMMI consensus published in the American Journal of Gastroenterology [19]. A study by Tougas et al. (N=123) established the normal values still referenced today, showing that gastric retention above 10% at 4 hours has a sensitivity of 93% for symptomatic gastroparesis [19].

Abdominal ultrasound is the initial imaging modality for suspected biliary disease. Sensitivity for gallstones exceeds 95%, and it can identify biliary ductal dilation suggesting obstruction [20].

CT abdomen/pelvis with contrast is reserved for suspected obstruction, pancreatitis complications, or mass lesions. It should not be used as a screening test for chronic nausea due to radiation exposure and low diagnostic yield in the absence of alarm features.

Wireless motility capsule (SmartPill) offers an ambulatory alternative to scintigraphy, measuring pH, pressure, and transit time throughout the entire GI tract. It can identify both gastroparesis and small-bowel dysmotility in a single study [21].

Red-Flag Symptoms That Demand Urgent Evaluation

Not all nausea warrants a methodical outpatient workup. Certain presentations require same-day or emergency evaluation.

The British Society of Gastroenterology identifies the following alarm features in their 2023 guideline on dyspepsia management [22]: hematemesis or melena, progressive dysphagia, unintentional weight loss exceeding 5% of body weight, persistent vomiting for more than 7 days, palpable abdominal mass, and iron-deficiency anemia with no other explanation.

New-onset nausea accompanied by severe headache and papilledema suggests raised intracranial pressure. This requires emergent neuroimaging (CT head without contrast as first-line) before any GI workup [8].

Nausea with chest pain, diaphoresis, or jaw pain in patients over 40 warrants cardiac evaluation. Inferior myocardial infarction commonly presents with nausea and vomiting as predominant symptoms, particularly in women and patients with diabetes, and this presentation accounts for missed MI diagnoses in approximately 2-5% of emergency department discharges, according to a 2020 analysis in Circulation [23].

Dr. Linda Nguyen, Clinical Professor of Gastroenterology at Stanford University, has noted: "The biggest mistake I see in nausea workups is anchoring on the GI tract too early. A basic metabolic panel and cardiac troponin can save a life when the real culprit is hyponatremia or a silent MI" [13].

Cyclic vomiting syndrome (CVS) affects approximately 2% of adults and is characterized by stereotypical episodes of intense nausea and vomiting lasting 24-72 hours separated by symptom-free intervals. The Rome IV criteria require at least three discrete episodes in the prior year with two in the prior six months, occurring at least one week apart, with an absence of vomiting between episodes [24]. Cannabis hyperemesis syndrome shares a similar pattern but is distinguished by compulsive hot bathing behavior and resolution with cannabis cessation.

Treatment Options Based on the Underlying Cause

Treatment for nausea depends entirely on the identified etiology. Empiric antiemetic therapy is appropriate for symptom control during the diagnostic workup but should not replace investigation of the root cause.

Ondansetron (Zofran) is the most commonly prescribed first-line antiemetic. A 5-HT3 receptor antagonist, it is effective for medication-induced, postoperative, and chemotherapy-related nausea. Standard dosing is 4-8 mg orally or sublingually every 8 hours as needed. The PONV meta-analysis by Carlisle and Stevenson (Cochrane Database, N=58,848 across 585 trials) demonstrated a number needed to treat (NNT) of 6 for prevention of postoperative nausea [25].

Metoclopramide is a dopamine D2 antagonist with prokinetic properties. It is FDA-approved for gastroparesis and diabetic gastric stasis at 5-10 mg before meals and at bedtime. Use beyond 12 weeks carries a black-box warning for tardive dyskinesia, with an estimated incidence of 0.1-1% per year of exposure [26].

Promethazine (Phenergan) targets histamine H1 and muscarinic receptors. It is particularly effective for vestibular-mediated nausea and motion sickness but causes significant sedation [2].

Proton pump inhibitors (PPIs) address nausea caused by GERD, peptic ulcer disease, and H. pylori-associated gastritis. Omeprazole 20 mg or pantoprazole 40 mg daily for 4-8 weeks is standard first-line acid suppression [18].

GLP-1-related nausea management requires a specific approach. The Endocrine Society recommends slow dose titration (increasing semaglutide at no less than 4-week intervals), smaller meal sizes, and avoidance of high-fat foods. If nausea persists despite conservative measures, holding at the current dose for an additional 4 weeks before escalation is preferred over adding an antiemetic long-term [7].

Gastroparesis management begins with dietary modification (small, frequent, low-fat, low-fiber meals) and prokinetic agents. For refractory cases, gastric peroral endoscopic myotomy (G-POEM) has shown promise: a 2020 multicenter study in Gastrointestinal Endoscopy (N=80) reported clinical response in 86% of patients at 12 months [27].

When to See a Specialist

Primary care evaluation is appropriate for the initial workup. Referral to gastroenterology is indicated when nausea persists beyond 4-8 weeks despite empiric treatment and a negative initial lab panel, when alarm features are present, or when gastroparesis is suspected [9].

Referral to endocrinology is warranted if adrenal insufficiency is confirmed, if thyroid disease is complicated (e.g., thyroid storm presenting with nausea and tachycardia), or if a pheochromocytoma is suspected based on episodic nausea with hypertensive surges [14].

Neurology referral is appropriate when nausea accompanies migraine (particularly abdominal migraine, which affects 1-4% of children and can persist into adulthood), intractable vertigo, or signs of raised intracranial pressure [8].

Psychiatric evaluation should be considered for functional nausea meeting Rome IV criteria: bothersome nausea occurring at least 3 days per week for at least 12 weeks, not exclusively associated with vomiting, and not explained by another medical condition. Cognitive behavioral therapy and tricyclic antidepressants (amitriptyline 10-25 mg nightly) have both demonstrated efficacy for functional nausea in randomized trials [24].

Medications That Commonly Cause Nausea

A medication review should precede any invasive testing. The following drug classes carry nausea rates above 10% in clinical trials:

GLP-1 receptor agonists. Semaglutide (Wegovy/Ozempic) caused nausea in 44.2% of participants in STEP-1 versus 17.7% with placebo at 68 weeks [7]. Tirzepatide (Mounjaro) produced nausea rates of 24-33% across the SURPASS trials, generally lower than semaglutide at equivalent weight-loss efficacy [28].

Metformin. GI side effects including nausea affect 20-30% of patients on immediate-release formulations. Extended-release metformin reduces this to approximately 10-15% [16].

SSRIs and SNRIs. Nausea occurs in 15-30% of patients initiating sertraline, escitalopram, or venlafaxine, typically peaking in the first 1-2 weeks and resolving by week 4 [29].

Opioids. Mu-receptor activation in the CTZ produces nausea in 25-40% of opioid-naive patients. Tolerance usually develops within 5-7 days of consistent use [2].

Antibiotics. Erythromycin (a motilin receptor agonist) causes nausea in 20-33% of patients. Azithromycin produces lower rates (approximately 5-10%). Metronidazole and doxycycline are intermediate offenders [30].

Iron supplements. Ferrous sulfate causes nausea in approximately 20% of patients. Taking it every other day rather than daily improves absorption and reduces GI side effects, based on a 2017 RCT in The Lancet Haematology (N=54) that showed superior fractional iron absorption with alternate-day dosing [31].

The standard approach when a medication is suspected: if clinically safe, discontinue or reduce the dose for 2-4 weeks and reassess. Symptom resolution confirms the association. If the medication cannot be stopped (e.g., chemotherapy), preemptive antiemetic protocols using the ASCO or MASCC guidelines should be applied [2].